

Erratum

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

Oliver A. Cornely, Rafael F. Duarte, Shariq Haider, Pranatharthy Chandrasekar, David Helfgott, Javier López Jiménez, Anna Candoni, Issam Raad, Michel Laverdiere, Amelia Langston, Nicholas Kartsonis, Marlou Van Iersel, Nancy Connelly and Hetty Waskin

J Antimicrob Chemother 2016; **71**: 718–26

In the key for Figure 2, the labelling of the curves should be reversed so that the black curve is labelled '300 mg (HSCT)' and the grey curve is labelled '300 mg (AML/MDS)'. The authors apologize for this error.